Choose Your Location
|
![]() |
INDIANAPOLIS (Map) -
WellPoint's affiliated health plans' decision to cover Treanda followed the Federal Drug Administration's decision to grant it orphan drug status for chronic lymphocytic leukemia. According to the National Cancer Institute, chronic lymphocytic leukemia is the second most common type of leukemia in adults, occurring most often during or after middle age.
"This medication can have a significant impact on our members with chronic
lymphocytic leukemia," said
WellPoint has a clinical guideline in place for "orphan" drug use. "Orphan" drugs refer to those medications that impact a relatively small percentage of the population, but may have a great impact on their overall health. WellPoint considers these drugs medically necessary when the drugs receive FDA marketing approval and the approval is made publicly available.
About WellPoint, Inc.
WellPoint, Inc. is the largest health benefits company in terms of medical
membership in the
|
|


